Navigation Links
Targeted agent shows promise for chronic lymphoid leukemia
Date:9/13/2010

COLUMBUS, Ohio Researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) have identified an experimental agent that targets chronic lymphocytic leukemia and perhaps other proliferative disorders of lymphocytes.

Their study shows that the small-molecule inhibitor CAL-101 directly promotes cell death by apoptosis in chronic lymphocytic leukemia (CLL) cells and disrupts several external survival pathways needed for CLL cell viability and proliferation.

The agent blocks a molecule called PI3K-delta, an isomer of the PI3K (phosphatidylinositol-3 kinase) pathway, which is activated mainly in blood-forming, or hematopoietic, cells.

The research used cells from patient tumors and was posted recently in the journal Blood.

"Overall, our findings provide a rationale for the development of CAL-101 as the first in a new class of targeted therapies for CLL," says principal investigator Amy J. Johnson, assistant professor of hematology and medicinal chemistry, and a CLL researcher in the OSUCCC-James.

"A PI3K inhibitor hasn't been developed yet because this pathway is required for many essential cellular functions, but the identification of PI3K-delta, which is hematopoietic-selective, unlocks a potential new therapy for B-cell malignancies," Johnson says.

CLL is the most common from of adult leukemia in the United States, with about 15,000 new cases and 4,500 deaths annually. An estimated 100,760 people in the United States are living with or are in remission from CLL.

People with the asymptomatic phase of CLL can live many years, even without treatment. But once the disease progresses to its symptomatic phase, treatment is required. This is usually a chemotherapy-based regimen that often induces remission. But current therapies are not curative and nearly all patients relapse.

The PI3K pathway is essential for survival of cells generally. This made it an unsuitable target for small molecule inhibitors until recently when research showed that PI3K-delta expression occurs mainly in hematopoietic cell types. Preclinical studies suggest that blocking this molecule may kill B cells with little toxicity to other hematopoietic cells.

The present study, which used CLL cells from patients, found the following:

  • CLL cells show high PI3K pathway activity and PI3K-delta expression;
  • CAL-101 preferentially kills CLL cells compared to normal B-cells;
  • CAL-101 selectively inhibits PI3K-delta and directly promotes apoptosis in primary CLL cells, and it disrupts multiple external survival pathways;
  • CAL-101 cell killing is caspase dependent and not diminished by the presence of stromal cells;
  • CAL-101 does not kill normal T-cells or NK cells or reduce antibody-dependent cellular cytotoxicity, but it does lower production of inflammatory and anti-apoptotic cytokines by activated T-cells.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Targeted strategies needed to find, prevent and treat breast cancer among Mexican-origin women
2. In Early Trial, Targeted Therapy Fights Advanced Melanoma
3. New targeted therapy for advanced melanoma associated with 80 percent response rate
4. Targeted drug leads to regression of metastatic melanoma with mutated BRAF gene
5. NYU Langone offers vascular-targeted photodynamic therapy for localized prostate cancer
6. Radiation device allows for targeted breast radiation to control cancer
7. Surveillance colonoscopy should be targeted to high-risk patients
8. Combined BRAF-targeted and immunotherapy shows promise for melanoma treatment
9. Experimental targeted therapy shows early promise against medulloblastomas
10. Targeted Therapy Shows Promise Against Deadly Brain Cancer
11. Targeted Radiation for Early Breast Cancer a Good Option: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. Justin Kolnick, Kara Diamond, ... teaching their patients about the key role this treatment plays in protecting oral health, ... endodontist. To better serve those who need a root canal in White Plains, NY ...
(Date:3/27/2017)... ... March 27, 2017 , ... SyncDog, Inc. , the ... partners LG Business Solutions at ATARC Federal Mobile Computing Summit , March ... provide education and examination into the mobility tools and technology employed by the ...
(Date:3/27/2017)... ... ... The Case Management Society of America (CMSA) will install six new members ... has elected their upcoming President-Elect, Secretary, Treasurer and two Directors to serve on the ... position has also been added to the BOD, per an appointment made by CMSA ...
(Date:3/27/2017)... ... March 27, 2017 , ... Advantexe ... announced the launch of a new research study, The Business Readiness Report. The ... execute that strategy, and the actual success of achieving individual and company goals. ...
(Date:3/27/2017)... ... ... is still in shock after receiving a $2,500 Academic Award from California Casualty . ... , She thinks the coming week is going to be a very joyful for her ... my students.” , The award will allow the 4th grade teacher at Tumwater Hill Elementary ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017  Twist Bioscience, a company accelerating science ... that it raised an additional $33 million. To date, ... "It is an exciting time to ... and continue to deliver industry-leading gene volume to our ... Emily M. Leproust, Ph.D., CEO of Twist Bioscience. "We ...
(Date:3/27/2017)... , March 27, 2017  PhaseRx, Inc. (NASDAQ: ... life-threatening inherited liver diseases in children, today reported ... year ended December 31, 2016 and provided an ... "PhaseRx continued to make progress during the fourth ... results from our non-human primate safety study, and with ...
(Date:3/27/2017)... , March 27, 2017 Invivotek, LLC, a ... in vivo pharmacology contract research organization (CRO), ... to its newly expanded preclinical research facility in ... provides a cleaner, renewable energy source to reduce costs ... Completion of the Genesis Solar Farm follows Invivotek,s recent ...
Breaking Medicine Technology: